Stemline Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells


The Company
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics that target both cancer stem cells (CSCs) and tumor bulk.
Clinical Trials
Cancer Stem Cells
Platform
Stemline Therapeutics has developed a Discovery Platform called StemScreen to identify novel compounds that target and kill CSCs.


News
&
Events
1/8/2015
Stemline Therapeutics Prices $59.85 Million Public Offering of Common Stock
1/7/2015
Stemline Therapeutics In-Licenses Novel Oral Small Molecule XPO1 Inhibitor
1/7/2015
Stemline Therapeutics Announces Proposed Public Offering of Common Stock
Copyright 2015 - Stemline Therapeutics, Inc. All rights reserved
Stemline